Buy-back Announced

AnaptysBio outstanding common stock share buy-back

US$100m consideration

Announced 27 Mar 2026

Advisers

AnaptysBio outstanding common stock

Target

Not disclosed

AnaptysBio

Acquirer

Financial adviser
Target
AnaptysBio outstanding common stock
Acquirer
AnaptysBio
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Pharma

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.